ライフサイエンスコーパス: systemic embolism

1 ke; p = 0.020, adjusted p = 0.023 for stroke/systemic embolism).

2 ned as stroke, transient ischemic attack, or systemic embolism.

3 been shown to reduce the risk of stroke and systemic embolism.

4 function is a potent predictor of stroke and systemic embolism.

5 The primary endpoint was stroke or systemic embolism.

6 ssociated with increased risk for stroke and systemic embolism.

7 bigatran 110 mg BID in preventing stroke and systemic embolism.

8 icantly increased risk of ischemic stroke or systemic embolism.

9 or the primary outcome of ischemic stroke or systemic embolism.

10 tion (OAC) to decrease the risk of stroke or systemic embolism.

11 farin for the primary end point of stroke or systemic embolism.

12 to warfarin for the prevention of stroke or systemic embolism.

13 utcome was ischemic or hemorrhagic stroke or systemic embolism.

14 ndpoint of stroke, cardiovascular death, and systemic embolism.

15 including stroke, myocardial infarction, and systemic embolism.

16 f cardiac thrombus formation associated with systemic embolism.

17 effect of apixaban on reduction of stroke or systemic embolism.

18 to apixaban for the prevention of stroke or systemic embolism.

19 The primary efficacy outcome was stroke or systemic embolism.

20 chemic attack with positive neuroimaging) or systemic embolism.

21 rms of the risk of having an ischemic stroke/systemic embolism.

22 prior stroke, transient ischemic attack, or systemic embolism.

23 dity and mortality due to related stroke and systemic embolism.

24 utcome was a composite of ischemic stroke or systemic embolism.

25 ctors of stroke/transient ischemic attack or systemic embolism.

26 of nonfatal stroke (ischemic/hemorrhagic) or systemic embolism (0.6/3.2/5.8/8.4[%]), risk of nonfatal

27 arin users in the risk of ischemic stroke or systemic embolism (1.24 versus 1.19 events per 100 perso

28 miodarone-treated patients had a stroke or a systemic embolism (1.58%/year vs. 1.19%/year; adjusted h

29 The incidence of stroke or systemic embolism (1.88% vs. 1.86%) and death (1.88% vs.

30 : 76%, transient ischemic attack [TIA]: 32%, systemic embolism: 1%).

31 associated with increased risk of stroke or systemic embolism: 1.1% for 1 to 5 episodes versus 1.2%/

32 closure, 58.6% underwent closure for stroke/systemic embolism, 10.2% for transient ischemia attack,

33 was associated with a higher rate of stroke/systemic embolism (13.6% vs. 3.2%, p = 0.021, p = 0.047

34 5%; RR, 0.89; 95% CI, 0.82-0.98), and stroke/systemic embolism (2.40% versus 3.13%; RR, 0.77; 95% CI,

35 BEV recipients had a higher rate of stroke/systemic embolism (20.0% versus 8.7%, adjusted OR: 2.46,

36 ncluding the composite of ischemic stroke or systemic embolism (7.4% vs 7.1%; P = 0.851), the composi

37 occlusion on the risk of ischemic stroke or systemic embolism, according to OAC use.

38 increased 5-year risk of ischemic stroke or systemic embolism (adjusted HR: 1.94; 95% CI: 1.15-3.29;

39 was significantly associated with stroke or systemic embolism, adjusted hazard ratio 1.98 (1.42-2.78

40 warfarin for the efficacy outcomes of stroke/systemic embolism, all-cause death, or myocardial infarc

41 point (ischemic stroke, hemorrhagic stroke, systemic embolism, all-cause mortality, and hospitalizat

42 in reducing the risk of recurrent stroke or systemic embolism among NAVIGATE ESUS participants with

43 s were ~10-fold more frequent than stroke or systemic embolism among this population on anticoagulati

44 ect of rivaroxaban and warfarin on stroke or systemic embolism among VKA-naive and VKA-experienced pa

45 The primary efficacy outcome was stroke or systemic embolism, analysed by intention to treat.

46 trial primary outcome of recurrent stroke or systemic embolism and (2) the trial secondary outcome of

47 0.65 (95% CI, 0.62-0.70) for ischemic stroke/systemic embolism and 0.69 (95% CI, 0.66-0.71) for major

48 AC naive had a smaller increase in stroke or systemic embolism and a similar lower rate of bleeding w

49 r of follow-up), the rate of ischemic stroke/systemic embolism and all-cause mortality (per 100 perso

50 The rate of ischemic stroke/systemic embolism and all-cause mortality (per 100 perso

51 The adjusted hazard ratio of ischemic stroke/systemic embolism and all-cause mortality was 0.55 (95%

52 had a lower rate of both ischemic stroke or systemic embolism and bleeding compared with those presc

53 n were not associated with risk of stroke or systemic embolism and did not modify the effect of apixa

54 For ischemic stroke/systemic embolism and for all-cause mortality, hazard ra

55 from 0.62 to 0.65 (p = 0.0009) for stroke or systemic embolism and from 0.59 to 0.69 for cardiac deat

56 mes were hospitalization for ischemic stroke/systemic embolism and hospitalization for major bleeding

57 he standard for assessing risk of stroke and systemic embolism and includes age and thromboembolic hi

58 Annualized event rates of stroke or systemic embolism and major bleeding and hazard ratios (

59 sed to DOACs had similar risks of stroke and systemic embolism and major bleeding as those exposed to

60 dysfunction have a higher risk of stroke or systemic embolism and major bleeding but show consistent

61 The observed incidence of stroke or systemic embolism and major bleeding events generally co

62 dated a prediction model for ischemic stroke/systemic embolism and major bleeding in patients with at

63 e clinical cohort, there were similar stroke/systemic embolism and major bleeding rates with dabigatr

64 ith the clinical outcomes of ischemic stroke/systemic embolism and major bleeding using univariate an

65 risks of hospitalization for ischemic stroke/systemic embolism and major bleeding versus warfarin.

66 f apixaban vs warfarin on rates of stroke or systemic embolism and major bleeding were consistent in

67 Five-year risks for ischemic stroke/systemic embolism and major bleeding were estimated with

68 efficacy and safety outcomes were stroke or systemic embolism and major bleeding.

69 F trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant

70 ictors of early ischaemic events (stroke/TIA/systemic embolism) and d-sICH.

71 me was a composite of major ischemic (stroke/systemic embolism) and hemorrhagic (intracerebral hemorr

72 outcomes, i.e., stroke (ischemic stroke and systemic embolism) and major bleeding in patients treate

73 mine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmaj

74 nial hemorrhage, the rate of ischemic stroke/systemic embolism, and all-cause mortality (per 100 pers

75 ng, heart failure hospitalization, stroke or systemic embolism, and all-cause mortality.

76 Efficacy outcomes were stroke or systemic embolism, and all-cause mortality.

77 The risks of mortality, stroke or systemic embolism, and bleeding were compared between ma

78 therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in nonvalvul

79 mpared to warfarin for prevention of stroke, systemic embolism, and cardiovascular death in patients

80 composite primary efficacy endpoint (stroke, systemic embolism, and cardiovascular death) is expresse

81 primary efficacy end point included stroke, systemic embolism, and cardiovascular death, and the pri

82 r preventing the combined outcome of stroke, systemic embolism, and cardiovascular death, as well as

83 mposite efficacy end point including stroke, systemic embolism, and cardiovascular/unexplained death,

84 ents of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascular/unexplained death.

85 rior stroke/transient ischemic attack, prior systemic embolism, and congestive heart failure were ass

86 statistics from 0.629 to 0.653 for stroke or systemic embolism, and from 0.591 to 0.731 for cardiac d

87 ary net clinical outcome of death, stroke or systemic embolism, and major bleeding and each individua

88 cause mortality, non-haemorrhagic stroke or systemic embolism, and major bleeding), adjusting for ba

89 eeding; apixaban 5 mg B.I.D. reduced stroke, systemic embolism, and mortality as well as major bleedi

90 attack, Caucasian race, hypertension, prior systemic embolism, and New York Heart Association functi

91 rent ischemic stroke, myocardial infarction, systemic embolism, and symptomatic deep vein thrombosis

92 ociated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) h

93 The primary efficacy outcome was stroke or systemic embolism, and the primary safety outcome was ma

94 Outcomes included the composite of stroke or systemic embolism, any stroke, and major bleeding among,

95 omposite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led t

96 he population attributable risk of stroke or systemic embolism associated with subclinical atrial tac

97 We compared the rates of stroke/systemic embolism at 1 year according to diabetes status

98 was a significantly increased risk of stroke/systemic embolism at 1 year versus either no diabetes (5

99 fectiveness (composite of ischemic stroke or systemic embolism at 18 months), and the rate of LAA occ

100 death, stroke, transient ischemic attack, or systemic embolism at 3 years.

101 te risk difference in incidence of stroke or systemic embolism at 3.5 years of follow-up was 7% (95%

102 omposite of death from any cause, stroke, or systemic embolism at 36 months.

103 omposite of death from any cause, stroke, or systemic embolism at 36 months.

104 anial haemorrhage, unclassifiable stroke, or systemic embolism at 90 days.

105 The cumulative rate of stroke and stroke/systemic embolism at follow-up were 13.6% and 15.9%, res

106 95% CI: -1.31, -0.75; p < 0.001), stroke or systemic embolism (B: -0.81; 95% CI: -0.90, -0.73; p < 0

107 fference in the primary outcome of stroke or systemic embolism between the intervention group and the

108 pixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear simila

109 xaban, compared with aspirin, reduced stroke/systemic embolism but increased major bleeding.

110 in statistically similar rates of stroke and systemic embolism, but apixaban had a lower risk of majo

111 was associated with a higher rate of stroke/systemic embolism, but not a higher mortality, at 30 day

112 The primary end point was stroke and systemic embolism by intention to treat.

113 was a significantly lower risk of stroke and systemic embolism (by 26%) for dabigatran (150 mg BID) c

114 vents (stroke, transient ischemic attack, or systemic embolism), cardiovascular death, clinically rel

115 tcome was stroke, transient ischemic attack, systemic embolism, cardiovascular death, major or nonmaj

116 ts (primary efficacy of composite of stroke, systemic embolism, cardiovascular/unexplained death, and

117 arfarin therapy for the prevention of stroke/systemic embolism/cardiovascular death, there was a sign

118 superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in

119 ter than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in

120 ral anticoagulant apixaban reduced stroke or systemic embolism compared with aspirin in people with s

121 ive rivaroxaban had a reduction in stroke or systemic embolism compared with those taking warfarin (1

122 as associated with lower rates of stroke and systemic embolism compared with warfarin, without an inc

123 scular death, myocardial infarction, stroke, systemic embolism, coronary revascularization, or acute

124 scular death, myocardial infarction, stroke, systemic embolism, coronary revascularization, or acute

125 Rates of ischemic stroke/systemic embolism, death, and bleeding.

126 consistently reduced the rate of stroke and systemic embolism, death, and major bleeding compared wi

127 KA-experienced patients to reduce stroke and systemic embolism, death, and the most serious types of

128 including stroke, non-central nervous system systemic embolism, death, myocardial infarction, and ble

129 t IDE trial were at a high risk of stroke or systemic embolism defined as a CHADS(2) score >=2 or CHA

130 as not associated with the risk of stroke or systemic embolism during follow-up (<1 hour: 1.0%/patien

131 omposite of cardiovascular death, stroke, or systemic embolism, evaluated in a time-to-event analysis

132 terval [CI], 1.16-1.5) but similar stroke or systemic embolism event rates (HR, 1.09; 95% CI, 0.88-1.

133 erienced significant reductions in stroke or systemic embolism, fatal and intracranial bleeding, and

134 there was no difference in risk of stroke or systemic embolism for the intervention group compared wi

135 The crude incidence of stroke and systemic embolism generally progressed alongside risk sc

136 rences, the long-term incidence of stroke or systemic embolism (hazard ratio [HR]: 1.38; 95% confiden

137 to 8.17; P<0.001) and of ischemic stroke or systemic embolism (hazard ratio, 2.49; 95% CI, 1.28 to 4

138 troke, nonfatal acute myocardial infarction, systemic embolism, heart failure development, or severe

139 th similar relative risks (RR) of stroke and systemic embolism, hemorrhagic stroke, myocardial infarc

140 .0001), with a similar finding for stroke or systemic embolism (HR, 0.655 [95% CI, 0.555-0.772]; and

141 these patients had higher rates of stroke or systemic embolism (HR, 1.47; 95% CI, 1.20-1.81) and majo

142 d to be more effective (outcome of stroke or systemic embolism: HR, 0.78; 95% CI, 0.67-0.91; vascular

143 n (HR, 1.53; 95% CI, 1.17-2.01 for stroke or systemic embolism; HR, 1.56; 95% CI, 1.27-1.93 for major

144 GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared

145 (13%), syncope or arrhythmia in 5 (10%), and systemic embolism in 3 (6%).

146 associated with the occurrence of stroke and systemic embolism in a large, international atrial fibri

147 ID reduced the primary outcome of stroke and systemic embolism in comparison with warfarin.

148 uperior to warfarin in preventing stroke and systemic embolism in nonvalvular atrial fibrillation, bu

149 erosis of the aorta is a potential source of systemic embolism in patients undergoing cardiac cathete

150 jor risk factor for perioperative stroke and systemic embolism in patients undergoing cardiac surgery

151 mpared with warfarin (n = 8657) on stroke or systemic embolism in patients with 1 dose-reduction crit

152 is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation a

153 to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation a

154 usion reduces the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation u

155 pared with warfarin for prevention of stroke/systemic embolism in patients with atrial fibrillation.

156 nferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation.

157 inferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.

158 ive and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation.

159 antagonists for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

160 ulation therapy for the prevention of stroke/systemic embolism in patients with atrial fibrillation.

161 an, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subcl

162 all indications except for the prevention of systemic embolism in patients with mechanical heart valv

163 ion of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial F

164 ion of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial F

165 antagonists (VKAs) for preventing stroke and systemic embolism in patients with non-valvular atrial f

166 ion of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial F

167 n agent, dabigatran, for reducing stroke and systemic embolism in patients with nonvalvular atrial fi

168 ndary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke

169 y over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly l

170 patients: HF in 110 (19%), VAs in 87 (15%), systemic embolisms in 18 (3%), and 34 (6%) died.

171 anial haemorrhage, unclassifiable stroke, or systemic embolism incidence at 90 days in a modified int

172 dditional factors associated with stroke and systemic embolism included elevated diastolic blood pres

173 ding death, myocardial infarction, stroke or systemic embolism, intracranial bleeding, major bleeding

174 ic hazard ratios (HRs) of ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), gastro

175 ted with reduced risk for ischemic stroke or systemic embolism, intracranial hemorrhage, and all-caus

176 found regarding risk for ischemic stroke or systemic embolism, intracranial hemorrhage, myocardial i

177 emic or hemorrhagic events (ischemic stroke, systemic embolism, intracranial or fatal extracranial bl

178 the primary endpoint of all-cause stroke or systemic embolism, ischaemic stroke, and all-cause morta

179 Associations with outcomes (total stroke or systemic embolism, ischemic stroke, cardiovascular death

180 rall and cardiovascular mortality, stroke or systemic embolism, ischemic stroke, major and intracrani

181 safety outcome was the composite of stroke, systemic embolism, major bleeding requiring transfusion,

182 ria (n = 751) were at higher risk for stroke/systemic embolism, major bleeding, and all-cause death t

183 Rates of stroke or systemic embolism, major bleeding, and all-cause mortali

184 Rates of stroke or systemic embolism, major bleeding, and mortality were co

185 The risks of stroke or systemic embolism, major bleeding, and mortality were hi

186 an compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality.

187 ed rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospit

188 ncidence of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or d

189 2) a composite end point of ischemic stroke, systemic embolism, major bleeding, or death; and (3) tot

190 Secondary outcomes were ischemic stroke or systemic embolism, major ischemic or hemorrhagic events

191 fied as "net clinical benefit" (all strokes, systemic embolism, MI, pulmonary embolism, major bleedin

192 Rates of stroke or systemic embolism, myocardial infarction, and bleeding w

193 an follow-up: 0.99 years) included stroke or systemic embolism, myocardial infarction, major bleeding

194 trial secondary outcome of recurrent stroke, systemic embolism, myocardial infarction, or cardiovascu

195 efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from

196 s associated with a higher risk of stroke or systemic embolism (n=206) independently of clinical char

197 l effectiveness end point of ischemic stroke/systemic embolism, no significant differences of the NOA

198 During the 30 days postprocedure, stroke or systemic embolism occurred after 16/4624 (0.35%) procedu

199 Stroke or systemic embolism occurred in 114 participants (4.8%) in

200 All-cause stroke or systemic embolism occurred in 4 patients (2.3% per year)

201 mean follow-up of 3.5+/-1.8 years, stroke or systemic embolism occurred in 55 patients in the apixaba

202 Stroke or systemic embolism occurred in 98 patients (1.3%) assigne

203 While the effects of local and systemic embolism on plant water transport and physiolog

204 t changes in the risk for ischemic stroke or systemic embolism or death without recent evidence of bl

205 se, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosi

206 and a composite clinical outcome of stroke, systemic embolism or major hemorrhage.

207 rence favoring novel oral anticoagulants for systemic embolism (OR, 0.84; 95% CI, 0.72-0.97; P=0.01),

208 001), and the composite of death, stroke, or systemic embolism (OR, 28.64 [95% CI, 21.24-38.61]; P<0.

209 0001) and the composite of death, stroke, or systemic embolism (OR, 3.42 [95% CI, 2.31-5.07]; P<0.000

210 e primary outcome was an ischemic (stroke or systemic embolism) or hemorrhagic (symptomatic intracran

211 s 7.1%; P = 0.851), the composite of stroke, systemic embolism, or cardiovascular death (20.3% vs 20.

212 efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death.

213 oninferiority), and the composite of stroke, systemic embolism, or cardiovascular/unexplained death (

214 d points included a composite of all stroke, systemic embolism, or cardiovascular/unexplained death a

215 defined as all-cause death, ischemic stroke, systemic embolism, or device or procedure-related events

216 whichever was later: death, ischemic stroke, systemic embolism, or device- or procedure-related event

217 ent TTR and the composite outcome of stroke, systemic embolism, or major hemorrhage.

218 e of SCAF in those with a history of stroke, systemic embolism, or transient ischemic attack was 39.4

219 comes were arterial thromboembolism (stroke, systemic embolism, or transient ischemic attack) and maj

220 CHA2DS2-VASc risk score; history of stroke, systemic embolism, or transient ischemic attack; and age

221 racranial hemorrhage, extracranial bleeding, systemic embolism, or vascular death within 30 days.

222 ial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days.

223 failure (HF), ventricular arrhythmias (VAs), systemic embolisms, or all-cause mortality.

224 ly decreased the risk for ischemic stroke or systemic embolism (p = 0.0004 and p = 0.0006, respective

225 statistic from 0.620 to 0.635 for stroke or systemic embolism (p = 0.0226), from 0.592 to 0.711 for

226 standard dose in the reductions in stroke or systemic embolism (p interaction = 0.26), major bleeding

227 ary efficacy analysis was rates of stroke or systemic embolism (per 100 patient-years) by intention t

228 20 +/- 5 months, the rates of death, stroke, systemic embolism, pericardial effusion, and major bleed

229 Stroke or systemic embolism (primary outcome), major bleeding (saf

230 ing 1.9 years, the annual rates of stroke or systemic embolism ranged from 0.74% in the bottom NT-pro

231 9 years follow-up, annual rates of stroke or systemic embolism ranged from 0.76% in the lowest hs-TnI

232 9-year period, the annual rates of stroke or systemic embolism ranged from 0.87% in the lowest hs-TnT

233 Annual rates of stroke or systemic embolism ranged from 0.9% to 2.03% (P<0.001); o

234 patients who were OAC naive had a stroke or systemic embolism rate of 0.6% (7 of 1255) compared with

235 patients who were OAC naive had a stroke or systemic embolism rate of 0.8% (10 of 1238) compared wit

236 ts who received amiodarone had a stroke or a systemic embolism rate of 1.24%/year versus 1.85%/year (

237 ho did not receive amiodarone, the stroke or systemic embolism rate was 1.29%/year versus 1.57%/year

238 Stroke and systemic embolism rates at 30 days were 0.8%, 0.3%, and

239 Stroke/systemic embolism rates during the at-risk period were s

240 In VKA-experienced patients, stroke and systemic embolism rates were 1.51%, 1.15%, and 1.74% per

241 In VKA-naive patients, stroke and systemic embolism rates were 1.57%, 1.07%, and 1.69% per

242 Stroke/systemic embolism rates were consistent among older (2.2

243 ated with significantly increased stroke and systemic embolism risk and a lower time in the therapeut

244 erior to well-managed warfarin for stroke or systemic embolism (S/SE) prevention and reduced bleeding

245 Outcomes included stroke and systemic embolism (S/SE), major bleeding, intracranial h

246 firmed apixaban noninferiority for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) versus tri

247 th aspirin, significantly reduced stroke and systemic embolism (SE) but increased major bleeding in p

248 AC) or warfarin for prevention of stroke and systemic embolism (SE) in AF.

249 l enlargement (LAE) is a predictor of stroke/systemic embolism (SE) in atrial fibrillation (AF) patie

250 irst composite coprimary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained de

251 rimary outcome was a composite of stroke and systemic embolism (SE).

252 atio, 1.21 [95% CI, 0.96-1.54] for stroke or systemic embolism [SE], 1.60 [95% CI, 1.32-1.95] for str

253 mary efficacy endpoint (composite of stroke, systemic embolism [SE], and cardiovascular/unexplained d

254 strong, independent predictor of stroke and systemic embolism, second only to prior stroke or transi

255 The pre-defined primary NCO (stroke/systemic embolism [SEE], major bleeding, death) was less

256 We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF)

257 his study is to evaluate rates of stroke and systemic embolism (SSE) in patients with cardiovascular

258 The outcomes were death, ischemic stroke/systemic embolism (SSE), major bleeding, and heart failu

259 e recurrent stroke/transient ischemic attack/systemic embolism, symptomatic intracerebral hemorrhage

260 troke, acute limb ischemia/major amputation, systemic embolism, symptomatic venous thromboembolism),

261 ixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of majo

262 ore enrollment had a lower risk of stroke or systemic embolism than patients with at least one episod

263 ociated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the pe

264 ffective as warfarin in preventing stroke or systemic embolism (the primary end point), because the p

265 The primary efficacy end point was stroke or systemic embolism; the safety end point we studied was m

266 reduction (ARR) of VKAs to prevent stroke or systemic embolism using 2 methods-first using a guidelin

267 r events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization

268 ng the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction

269 23 to aspirin), the annual rate of stroke or systemic embolism was 0.74% (n=48; 95% CI 0.55 to 0.98)

270 revious stroke or TIA, the rate of stroke or systemic embolism was 1.01 per 100 patient-years of foll

271 in), among whom the annual rate of stroke or systemic embolism was 1.20% (n=7; 95% CI 0.48 to 2.48) w

272 revious stroke or TIA, the rate of stroke or systemic embolism was 2.46 per 100 patient-years of foll

273 The incidence rate of ischemic stroke or systemic embolism was 6.6 per 1000 person-years for adul

274 Analysis of stroke or systemic embolism was based on intention to treat.

275 occlusion on the risk of ischemic stroke or systemic embolism was consistent after discharge across

276 of rivaroxaban versus warfarin on stroke or systemic embolism was consistent: Rates per 100 patient-

277 (6 randomized controlled trials, n=30,699), systemic embolism was favored with novel oral anticoagul

278 high NT-proBNP group, the risk of stroke or systemic embolism was higher compared with the low NT-pr

279 otic therapy, the risk of ischemic stroke or systemic embolism was lower with concomitant left atrial

280 n the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with

281 risk of hospitalization for ischemic stroke/systemic embolism was significantly lower between DOACs

282 All-cause stroke or systemic embolism was similar between both strategies (1

283 The primary efficacy outcome, stroke or systemic embolism, was assessed in the intention-to-trea

284 e TTR quartiles, hazard ratios for stroke or systemic embolism were 0.73 (95% confidence interval [CI

285 Rates of stroke or systemic embolism were 1.46% and 1.60%/y on dabigatran 1

286 tes per 100 person-years for ischemic stroke/systemic embolism were 2.2, 1.4, 2.6, and 4.4 for DOACs

287 3-2.30]), whereas 1-year rates for stroke or systemic embolism were 3.0% and 3.3% in apixaban and war

288 -1.00; P = .046), whereas rates of stroke or systemic embolism were comparable.

289 Risks of bleeding and stroke/systemic embolism were compared by apixaban dose (5 vers

290 ates for ischemic stroke and ischemic stroke/systemic embolism were explored.

291 The rates of stroke or systemic embolism were lower with dabigatran 150 mg and

292 Stroke and systemic embolism were not significantly different betwe

293 ninferior to warfarin in reducing stroke and systemic embolism, whether patients received antiplatele

294 AF did not modify the reduction in stroke or systemic embolism with apixaban (P(interaction)=0.1).

295 on did not modify the reduction in stroke or systemic embolism with apixaban (P(trend)=0.1).

296 absolute reduction in the rate of stroke and systemic embolism with apixaban versus warfarin was 0.77

297 absolute risk reduction for ischemic stroke/systemic embolism with dabigatran 150 mg twice daily ran

298 riate showed that the reduction in stroke or systemic embolism with LAA occlusion was similar whether

299 GS: Apixaban significantly reduced stroke or systemic embolism with no evidence of a differential eff

300 . was noninferior to warfarin for stroke and systemic embolism without a difference in major bleeding

301 te 150 mg B.I.D. reduced the rates of stroke/systemic embolism without any difference in major bleedi